Cellectric is developing a direct-from-blood application for sepsis samples, selectively destroying human cells in the patient sample with the aim to bypass the need for culturing of the bacteria. The technology focuses on isolating target bacteria within minutes to accelerate the sepsis diagnosis workflow, with the goal of enabling faster, more effective sepsis patient management.
“We are excited to join forces with Gradientech, whose ultra-rapid AST platform is already setting new standards in clinical microbiology,” says Terje Wimberger, Managing Director at Cellectric. “Together, we will explore how the technology of Cellectric can resolve sample complexity and improve overall workflow efficiency, ultimately contributing to faster, more accurate treatment decisions for sepsis patients worldwide.”
“Cellectric’s cutting-edge approach to rapidly isolating bacteria directly from whole blood is true innovation. When combined with the ultra-rapid QuickMIC system, we can together not just improve workflows—we can redefine what’s possible in sepsis diagnostics and set a new benchmark for innovation in the clinical diagnostics market,” says Sara Thorslund, co-founder and CEO at Gradientech.
QuickMIC® and its gram-negative panel are CE marked and commercially available in Europe. QuickMIC is classified as a Breakthrough Device by the U.S. Food and Drug Administration and available for Investigational Use Only in the U.S., but not 510(k) cleared.
About Gradientech
Gradientech is a leader in ultra-rapid antibiotic susceptibility testing, developing next-generation diagnostics for infectious disease medicine. Our innovative diagnostic solutions aim to save lives, reduce healthcare costs, and combat the spread of antibiotic resistance – one of our greatest global health threats. Gradientech is headquartered in Uppsala, Sweden. Visit gradientech.se for more information.
About Cellectric
Founded in 2021 as a spin- off from the Austrian Institute of Technology, Cellectric has developed a new way of manipulating cell-containing media using state-of-the-art dielectric materials to induce highly targeted electrodynamic effects, which allows for the selective permeabilization or destruction of specific target cells in a complex sample. Cellectric is initially looking to apply its proprietary technology in sepsis and sepsis-adjacent indications, where the platform can be used to rapidly isolate and identify bacteria, hastening the pace at which diagnoses can be made. Visit cellectric.com for more information.
For further information, please contact:
Sara Thorslund, PhD, CEO
Tel: +46 736 29 35 80
sara.thorslund(at)gradientech.se
Terje Wimberger, PhD, Managing Director
Tel: +43 676 43 41 666
terje.wimberger(at)cellectric.com